US EditionEMPACT-MI analysis “reassuring” on use of empagliflozin in patients with poor kidney function - Cardiovascular News
Summary by Cardiovascular News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
EMPACT-MI analysis “reassuring” on use of empagliflozin in patients with poor kidney function - Cardiovascular News
Deepak L Bhatt. Photo by © ACC/Phil McCarten 2025 Keywords: Media, LBCT; ACC.25; Empagliflozin preserved kidney function and was safe to initiate in heart attack patients, findings of a secondary analysis of the EMPACT-MI trial, published in nature cardiovascular research have shown. EMPACT-MI is a multicentre, randomised, parallel-group, double-blind, placebo-controlled superiority trial investigating the effect of the SGLT2 inhibitor empaglifl…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
